Emergent BioSolutions, Inc. (EBS)
A biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics. The Company operates in two business segments: biodefense and commercial.
Recs
59special
(< 20)
Submitted: 9/21/2009 5:21:23 PM :
Start Price:
$19.02
EBS Score:
-17.75
2/162 in Biotechnology -(84.2 @ A+/A-)
Recs
blackmonday2007
(< 20)
Submitted: 9/15/2009 11:52:59 AM :
Start Price:
$19.59
EBS Score:
-22.12
MIKE TURNER PICK
Recs
cayamax
(< 20)
Submitted: 9/11/2009 11:09:20 AM :
Start Price:
$19.27
EBS Score:
-21.09
Sadly, bioterrorism and biowarfare will be a threat for quite awhile.
Recs
dantefromsomm
(22.72)
Submitted: 9/3/2009 11:50:30 PM :
Start Price:
$17.54
EBS Score:
-17.45
Very high insider ownership with alot of potential for blow ups with product develope ments.Same basic formula i like.Increasing balance sheets, reasonably low p/e,good insider ownership,low debt.
Recs
Ulenspiegel101
(64.19)
Submitted: 6/2/2009 3:07:11 PM :
Start Price:
$11.89
EBS Score:
+17.97
proven innovator
Recs
JohanHansen
(72.65)
Submitted: 5/6/2009 1:08:06 PM :
Start Price:
$9.61
EBS Score:
+44.09
2nd Chance after -28%
Recs
MessyBurrito
(71.60)
Submitted: 4/21/2009 3:31:36 AM :
Start Price:
$10.92
EBS Score:
+12.70
Doesn't look lovely but has been drastically oversold- should see a decent reversal within a few trading days
Recs
SwordAgain
(82.47)
Submitted: 2/24/2009 12:56:37 AM :
Start Price:
$21.05
EBS Score:
-70.42
2/24/09 Pitch: Upthumb. Earnings 3/5/09, 5:00 PM. Excellent price to cash flow for a biotech. Great product pipeline. Deserves higher P/E. Headed back to $27.
Recs
Tyrone85
(98.70)
Submitted: 2/19/2009 9:57:09 PM :
Start Price:
$21.02
EBS Score:
-67.63
after/ 1st q of 2009
Recs
fivehaus
(47.87)
Submitted: 2/19/2009 9:56:35 AM :
Start Price:
$22.59
EBS Score:
-67.23
Daily, weekly. monthly trends are up. Increasing sales, increasing earnings. a good sales base with the U.S. Military.
Recs
cjstock02
(24.84)
Submitted: 1/28/2009 2:59:20 PM :
Start Price:
$21.11
EBS Score:
+50.43
We developed a gap down after a long run up. That looks very bearish on the chart.
Recs
sprucemoose2
(87.05)
Submitted: 1/5/2009 2:27:31 PM :
Start Price:
$26.07
EBS Score:
-57.40
has a constant revenue stream from the good ole US of A and sticks to its 50 day MA very well
Recs
BlindLuck32
(81.12)
Submitted: 12/24/2008 10:02:33 AM :
Start Price:
$24.35
EBS Score:
-62.07
Makers of Anthrax vaccine for the military and other biodefense products, which require regular boosters. Relative low P/E. Up 80% since October and I haven't seen the ceiling yet.
Recs
viasyncro
(60.31)
Submitted: 12/20/2008 12:34:07 PM :
Start Price:
$25.97
EBS Score:
-62.78
Niche company with growing market share
Recs
cdriver
(< 20)
Submitted: 12/15/2008 2:30:27 PM :
Start Price:
$20.44
EBS Score:
-51.32
Demand on the rise.
Recs
MalibuGuru
(< 20)
Submitted: 12/9/2008 5:08:54 PM :
Start Price:
$24.40
EBS Score:
-57.48
Emergent BioSolutions maintains a large economic moat through it's Biothrax vaccine. Two of it's vaccines in late stage development, a typhoid vaccine candidate and a hepatitis B therapeutic vaccine candidate, uniquely positions EBS to take advantage of the expected huge growth of demand in LDC and MDC.
Recs
DNAdivaSTL
(< 20)
Submitted: 12/2/2008 4:18:53 PM :
Start Price:
$13.48
EBS Score:
+30.96
When your biggest customer is Big Brother, growth is inevitable....
Recs
GEORGYVON
(< 20)
Submitted: 12/2/2008 1:01:27 PM :
Start Price:
$23.85
EBS Score:
-63.73
Speculation more than one year is too uncertain.
Recs
Recs
xiaolifeidao
(97.86)
Submitted: 11/26/2008 2:09:28 PM :
Start Price:
$20.93
EBS Score:
-51.11
The only Anthrax vaccine provider. U.S. has the possibility of engagement of small scale warfares in Mid-east and Asia in the next 5 years, so there are still strong requirement of the Anthrax vaccine.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 49 1 2 3 Next »